The latest report from Growth Plus Reports analyzes the product, potential applications, demand, major manufacturers, and SWOT analysis of the global rheumatic heart disease management market.
The rheumatic heart disease management market report assists in determining the best distribution channels for certain products and possible markets for new product launches. You can get insights into valuable data, important statistics, trends, and competitive landscape information in this market through comprehensive TOC, Tables, and Charts presented throughout the report.
Key Takeaways:
- The increasing government initiatives and funding for rheumatic heart disease research will support the market’s growth.
- The growth in the prevalence of the disease will drive demand for rheumatic heart disease management.
- North America dominates the global rheumatic heart disease management market.
Request a Free Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/rheumatic-heart-disease-management-market/8462
Rheumatic Heart Disease Management Market Scope
|
Report Attribute |
Details |
|
Market size value in 2022 |
US$ 1.10 billion |
|
Revenue forecast in 2031 |
US$ 1.66 billion |
|
Growth Rate |
CAGR of 4.7% from 2023 to 2031 |
|
Base year for estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments covered |
Drug Class, End User, and Region |
| Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
Market Drivers
The rising prevalence of rheumatic heart disease, increased awareness of the disease, and medical technology advancements will drive the revenue growth of the rheumatic heart disease management market. Furthermore, increased demand for rheumatic heart disease management products and services is expected to boost the market revenue growth rate. Additionally, increasing government initiatives and funding for rheumatic heart disease research will support the market’s revenue growth.
Market Segmentation
Growth Plus Reports has analyzed the global rheumatic heart disease management market from three perspectives: Drug Class, End User, and Region.
Drug Class Segmentation: Based on the drug class, the global rheumatic heart disease management market is segmented into anti-inflammatory, anti-coagulant, antibiotics, and others. The antibiotics segment dominates the market with the largest revenue share because they are essential to managing and preventing rheumatic heart disease and are widely used to treat infection.
End-User Segmentation: Based on the end-user, the global rheumatic heart disease management market is segmented into hospitals, ambulatory surgical centers, and others. The hospital segment dominates the market because hospitals are highly equipped with the essential knowledge and tools needed to diagnose and manage rheumatic heart disease effectively and are critical for patients who require immediate medical assistance for rheumatic heart disease-related problems.
Regional Growth Dynamics
Based on the region, the global rheumatic heart disease management market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America dominates the global rheumatic heart disease management market with the largest revenue share. Increasing urbanization, growth in the prevalence of cardiac disease, the rapid adoption of advanced technologies in various stent materials, and better healthcare infrastructure are attributed to North America’s significant revenue share in the global market.
Request for Customization – https://www.growthplusreports.com/inquiry/customization/rheumatic-heart-disease-management-market/8462
Competitive Landscape
The major players operating in the global rheumatic heart disease management market are:
- Pfizer Inc.
- GlaxoSmithKline Plc.
- Sanofi S.A.
- Abbott Laboratories Inc.
- Merck & Co. Inc.
- Novartis AG
- F. Hoffmann-La Roche Ltd.
- Bayer AG
- Cipla Inc.
The rheumatic heart disease management devices market is slightly competitive, with several international players involved. Market leaders focus on technological advancements, research and development activities, mergers, and acquisitions to strengthen their market presence.
Recent developments:
- Cardiol Therapeutics announced FDA Investigational New Drug Application (IND) Authorization for Cardiolrx Multicenter Phase II Open-label Pilot Study for Recurrent Pericarditis in May 2022.
- Kiniksa Pharmaceuticals, Ltd. announced in March 2021 that the United States Food and Drug Administration (FDA) approved ARCALYST (rilonacept), a weekly, subcutaneously injected, recombinant fusion protein that blocks interleukin-1 alpha (IL-1a) and interleukin-1 beta (IL-1) signaling, for the treatment of recurrent pericarditis and risk reduction in adults and children 12 years and older.
Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8462
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- ‘Business Profile’ of Key Players
Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction
Visit our report store at – https://www.growthplusreports.com/report-store
Browse related reports:
Facial Injectables Market by Product (Botulinum Toxin [Botox], Collagen, and Hyaluronic Acid), by Application (Aesthetics & Therapeutics) and End User (Hospitals & Dermatologic Clinics) – Global Outlook and Forecast 2020-2030
Disposable Medical Devices Market by Product Type (Wound Management Products, Sterilization Supplies), Raw Material (Plastic Resins, Nonwoven Material), and End User (Hospitals and Home Healthcare) – Global Outlook & Forecast 2022-2030
Idiopathic Pulmonary Fibrosis Market by Drug Class (Tyrosine Kinase Inhibitors, Antifibrotic Agents), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2022-2030
Global Critical Care Antiarrhythmic Drugs Market by Drug Class (Beta Blockers, Calcium Channel Blockers), Disease Type (Supraventricular Arrhythmias, Ventricular Arrhythmias) – Global Outlook & Forecast 2022-2030
Gene Therapy Market by Vector Type (Viral, Non-Viral), Delivery Type (Ex-Vivo, In-Vivo), Application (Oncology, Cardiology, Neurology), End-user (Hospitals, Ambulatory Centers)– Global Outlook & Forecast 2022-2030
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.
Contact:
Manan Sethi
Director, Market Insights
Email: sales@growthplusreports.com
256 Chapman Road
STE 105-4, Newark,
New Castle – 19702, USA
Phone no: +1 888 550 5009
Web: https://www.growthplusreports.com/